South America Hemangioblastoma Market

ID: MRFR/HC/54544-HCR 200 Pages Rahul Gotadki Last Updated: September 17, 2026
South America Hemangioblastoma Market Research Report By Tumor Site (Brain, Spinal Cord, Retina), By Diagnosis (CT Scan, MRI Scan, Others), By Treatment (Surgery, Chemotherapy, Radiotherapy, Corticosteroids, Anticonvulsants, Others) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth & Industry Forecast 2025 To 2035
South America Hemangioblastoma Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)7.87%
2024 Market Size$ 266.21 Million
2025 Market Size$ 287.16 Million
2035 Market Size$ 612.66 Million
Key Players
Novartis
Bristol-Myers Squibb
Roche
Merck & Co.
Amgen
Eli Lilly and Company
Trends
  • Rising Awareness and Diagnosis
  • Advancements in Treatment Options
  • Regulatory Support for Research
Opportunities
  • Increasing Incidence Rates
  • Investment in Research and Development
  • Technological Advancements in Diagnostics
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Medical Device, BY Tumor Site (USD Million)
      1. 4.1.1 Brain
      2. 4.1.2 Spinal Cord
      3. 4.1.3 Retina
    2. 4.2 Medical Device, BY Diagnosis (USD Million)
      1. 4.2.1 CT Scan
      2. 4.2.2 MRI Scan
      3. 4.2.3 Angiogram
    3. 4.3 Medical Device, BY Treatment (USD Million)
      1. 4.3.1 Surgery
      2. 4.3.2 Chemotherapy
      3. 4.3.3 Radiotherapy
      4. 4.3.4 Corticosteroids
      5. 4.3.5 Anticonvulsants
    4. 4.4 Medical Device, BY Radiotherapy (USD Million)
      1. 4.4.1 Conformal Radiotherapy
      2. 4.4.2 Intensity Modulated Radiotherapy (IMRT)
      3. 4.4.3 Stereotactic Radiotherapy
      4. 4.4.4 Radiosurgery
    5. 4.5 Medical Device, BY Corticosteroids (USD Million)
      1. 4.5.1 Hydrocortisone
      2. 4.5.2 Dexamethasone
      3. 4.5.3 Methylprednisolone
      4. 4.5.4 Prednisolone
    6. 4.6 Medical Device, BY Anticonvulsants (USD Million)
      1. 4.6.1 Carbamazepine
      2. 4.6.2 Lamotrigine
      3. 4.6.3 Levetiracetam
      4. 4.6.4 Phenytoin
      5. 4.6.5 Sodium Valproate
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Medical Device
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Medical Device
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Novartis (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bristol-Myers Squibb (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Roche (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Merck & Co. (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Amgen (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Eli Lilly and Company (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 AstraZeneca (GB)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Pfizer (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Sanofi (FR)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 SOUTH AMERICA MARKET ANALYSIS BY TUMOR SITE
    3. 6.3 SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS
    4. 6.4 SOUTH AMERICA MARKET ANALYSIS BY TREATMENT
    5. 6.5 SOUTH AMERICA MARKET ANALYSIS BY RADIOTHERAPY
    6. 6.6 SOUTH AMERICA MARKET ANALYSIS BY CORTICOSTEROIDS
    7. 6.7 SOUTH AMERICA MARKET ANALYSIS BY ANTICONVULSANTS
    8. 6.8 KEY BUYING CRITERIA OF MEDICAL DEVICE
    9. 6.9 RESEARCH PROCESS OF MRFR
    10. 6.10 DRO ANALYSIS OF MEDICAL DEVICE
    11. 6.11 DRIVERS IMPACT ANALYSIS: MEDICAL DEVICE
    12. 6.12 RESTRAINTS IMPACT ANALYSIS: MEDICAL DEVICE
    13. 6.13 SUPPLY / VALUE CHAIN: MEDICAL DEVICE
    14. 6.14 MEDICAL DEVICE, BY TUMOR SITE, 2024 (% SHARE)
    15. 6.15 MEDICAL DEVICE, BY TUMOR SITE, 2024 TO 2035 (USD Million)
    16. 6.16 MEDICAL DEVICE, BY DIAGNOSIS, 2024 (% SHARE)
    17. 6.17 MEDICAL DEVICE, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
    18. 6.18 MEDICAL DEVICE, BY TREATMENT, 2024 (% SHARE)
    19. 6.19 MEDICAL DEVICE, BY TREATMENT, 2024 TO 2035 (USD Million)
    20. 6.20 MEDICAL DEVICE, BY RADIOTHERAPY, 2024 (% SHARE)
    21. 6.21 MEDICAL DEVICE, BY RADIOTHERAPY, 2024 TO 2035 (USD Million)
    22. 6.22 MEDICAL DEVICE, BY CORTICOSTEROIDS, 2024 (% SHARE)
    23. 6.23 MEDICAL DEVICE, BY CORTICOSTEROIDS, 2024 TO 2035 (USD Million)
    24. 6.24 MEDICAL DEVICE, BY ANTICONVULSANTS, 2024 (% SHARE)
    25. 6.25 MEDICAL DEVICE, BY ANTICONVULSANTS, 2024 TO 2035 (USD Million)
    26. 6.26 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TUMOR SITE, 2025-2035 (USD Million)
      2. 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
      3. 7.2.3 BY TREATMENT, 2025-2035 (USD Million)
      4. 7.2.4 BY RADIOTHERAPY, 2025-2035 (USD Million)
      5. 7.2.5 BY CORTICOSTEROIDS, 2025-2035 (USD Million)
      6. 7.2.6 BY ANTICONVULSANTS, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

South America South America Hemangioblastoma Market Segmentation

South America Hemangioblastoma Market By Tumor Site (USD Million, 2025-2035)

  • Brain
  • Spinal Cord
  • Retina

South America Hemangioblastoma Market By Diagnosis (USD Million, 2025-2035)

  • CT Scan
  • MRI Scan
  • Angiogram

South America Hemangioblastoma Market By Treatment (USD Million, 2025-2035)

  • Surgery
  • Chemotherapy
  • Radiotherapy
  • Corticosteroids
  • Anticonvulsants

South America Hemangioblastoma Market By Radiotherapy (USD Million, 2025-2035)

  • Conformal Radiotherapy
  • Intensity Modulated Radiotherapy (IMRT)
  • Stereotactic Radiotherapy
  • Radiosurgery

South America Hemangioblastoma Market By Corticosteroids (USD Million, 2025-2035)

  • Hydrocortisone
  • Dexamethasone
  • Methylprednisolone
  • Prednisolone

South America Hemangioblastoma Market By Anticonvulsants (USD Million, 2025-2035)

  • Carbamazepine
  • Lamotrigine
  • Levetiracetam
  • Phenytoin
  • Sodium Valproate

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.